USCOM LIMITED — Regulatory Filings 2016

Mar 30, 2016

ASX Media Release

Paediatric sepsis mortality reduced 46% with USCOM use: New Thai critical care study.

Sydney, Australia: 31st March 2016: Uscom (ASX code: UCM) (the Company or Uscom ), a revenue stage, cardiovascular and pulmonary health technology company, today released to market the results of a study from the Chulalongkorn University Department of Paediatrics and the King Chulalongkorn Memorial Hospital demonstrating a reduction in mortality of 46% in paediatric fluid refractory septic shock patients using USCOM 1A.

==> picture [359 x 114] intentionally omitted <==

==> picture [359 x 113] intentionally omitted <==

Septic Shock Mortality in King Chulalongkorn Memorial Hospital – Uscom use began in 2013.

The study, of 6 month to 14 year olds with severe infections, found USCOM aided treatment in 71% of patients, reduced total fluid loading, and reduced mortality by a relative 46%, from 19% to 10.2%, since adopting the USCOM 1A and Australian Professor Brendan Smith’s approach to septic shock management.

Professor Brendan Smith presented similar findings at the Society of Critical Care Medicine Annual Scientific meeting in 2012, and was nominated for Australian of the Year in 2014 for his work on implementing improved septic shock management in regional Australia. Similar results were published by Kings College in London in 2013 where USCOM guided management has been implemented and reduced pediatric sepsis mortality by a relative 35% from 17% to 11%.

Professor Smith said “These results are consistent with our findings, and the findings of others worldwide. The early and accurate measurement of haemodynamics using USCOM allows us to non-invasively and rapidly initiate appropriate treatment, saving vital minutes and patients lives.

The study was presented by Critical Care Doctors from Thailand’s King Chulalongkorn Memorial Hospital on 23rd of March at the Thai Paediatric Respiratory and Critical Care Society Annual Scientific Meeting.

Sepsis kills over 6 million children and neonates per year, while fluid refractory septic shock, associated with severe infections, is responsible for the death of approximately 70% of all children who die worldwide.

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

ASX Media Release

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “If USCOM was adopted worldwide and achieved only a 35% reduction in mortality, this could save over 2 million children a year. Sepsis is a serious global health issue and USCOM is changing the balance; it is now the responsibility of public health providers to take notice of the evidence. As superbugs become more virulent, the significance of Uscom technology will become more critical. These results demonstrate that USCOM has the same impact in Thailand as it does in Australia, London and the US. The USCOM 1A technology is recommended in the Global Paediatric Sepsis Guidelines as a preferred method to manage children with sepsis.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

References:

Thongnual C, Hantragool S, Samransamriatkit R. Efficacy of non-invasive cardiac monitoring (Ultrasonic Cardiac Output Monitor) guide in management of fluid refractory pediatric septic shock. Pediatric Respiratory and Critical Care Medicine Association,, Annual Scientific Meeting. 2016; proceedings.

Deep A, Goonasekera CDA, Wang Y, Brierley J. Evolution of haemodynamics and outcome of fluid refractory septic shock in children. Int Care Med 2013 DOI 10.1007/s00134-013-3003-z

Smith BE, Phillips RA, Madigan V, West MJ. Decreased Mortality, Morbidity and Emergency Transport in Septic Shock; A New Protocol Based on Advanced Noinvasive Haemodynamics (USCOM) and Early Antibiotics. Crit Care Med 2012; 40(12):1023. doi: 10.1097/01.ccm.0000424114.76434.7a

http://www.world-sepsis-day.org/?MET=SEPSISSTART&vPRIMNAVISELECT=3 (Accessed 30 Mar 2016)

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom SpiroSonic spirometers. All Uscom devices are premium resolution, and deploy innovative and practice leading technologies with FDA, CE, CFDA and TGA regulatory approval, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial diseases and monitoring of pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Associate Professor Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au